Trial reportRespiratory research2019
Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis.
Trial report in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02951416 (The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank), which is not on this map. Cited by 33 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)
Who cites it
33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Psychometric properties of health-related quality of life assessment instruments in idiopathic pulmonary fibrosis: a systematic review applying COSMIN methodology.Health and quality of life outcomes · 2026Pooled it
- Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Health and quality of life outcomes · 2025Pooled it
- Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2023Pooled it
- Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis.BMJ open · 2022Pooled it
- Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Trial
- Quality of life questionnaires in patients with acromegaly: a scoping review.Journal of patient-reported outcomes · 2026Article
- The Patient Journey in Interstitial Lung Disease: Mobility, Independence, and Psychological Burden.Journal of clinical medicine · 2025Article
- Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis.CHEST pulmonary · 2025Article
- Article
- Article
- Functional Measures in Non-COPD Chronic Respiratory Diseases: A Systematic Review.Journal of clinical medicine · 2024Review
- Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis.ERJ open research · 2024Article
- The Rationale, Evidence, and Adaptations to Pulmonary Rehabilitation for Chronic Respiratory Diseases Other Than COPD.Respiratory care · 2024Review
- Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis.Journal of patient-reported outcomes · 2024Article
- Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study.Health science reports · 2023Article
- Serum Krebs von den Lungen-6: promising biomarker to differentiate CPFE from IPF.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study.Pituitary · 2022Article
- Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.Respiratory research · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a rare disease with a median survival of 3-5 years after diagnosis with limited treatment options. The aim of this study is to assess the psychometric characteristics of the Short Form 36 Health Status Questionnaire (SF-36) in IPF and to provide disease specific minimally important differences (MID).
methodsData source was the European IPF Registry (eurIPFreg). The psychometric properties of the SF-36 version 2 were evaluated based on objective clinical measures as well as subjective perception. We analysed acceptance, feasibility, discrimination ability, construct and criterion validity, responsiveness and test-retest-reliability. MIDs were estimated via distribution and anchor-based approaches.
resultsThe study population included 258 individuals (73.3% male; mean age 67.3 years, SD 10.7). Of them 75.2% (194 individuals) had no missing item. The distribution of several items was skewed, although floor effect was acceptable. Physical component score (PCS) correlated significantly and moderately with several anchors, whereas the correlations of mental component score (MCS) and anchors were only small. The tests showed mainly significant lower HRQL in individuals with long-term oxygen therapy. Analyses in stable individuals did not show significant changes of HRQL except for one dimension and anchor. Individuals with relevant changes of the health status based on the anchors had significant changes in all SF-36 dimensions and summary scales except for the dimension PAIN. PCS and MCS had mean MIDs of five and six, respectively. Mean MIDs of the dimensions ranged from seven to 21.
conclusionIt seems that the SF-36 is a valid instrument to measure HRQL in IPF and so can be used in RCTs or individual monitoring of disease. Nevertheless, the additional evaluation of longitudinal aspects and MIDs can be recommended to further analyse these factors. Our findings have a great potential impact on the evaluation of IPF patients.
trial registrationThe eurIPFreg and eurIPFbank are listed in https://clinicaltrials.gov ( NCT02951416 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.